Education
About Us
Working with TipRanks
Follow Us
Finch Therapeutics Group (FNCH)
OTHER OTC:FNCH
FNCH Stock Chart & Stats
$12.70
-$0.05(-0.45%)
At close: 4:00 PM EST
$12.70
-$0.05(-0.45%)
Day’s Range― - ―
52-Week Range$11.50 - $16.10
Previous CloseN/A
Volume338.00
Average Volume (3M)6.04K
Market Cap
$20.19M
Enterprise Value$38.81M
Total Cash (Recent Filing)$16.04M
Total Debt (Recent Filing)$28.99M
Price to Earnings (P/E)―
Beta1.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,605,763
10 Day Avg. Volume2,609
30 Day Avg. Volume6,039
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)54.13
P/FCF Ratio-0.18
Enterprise Value/Market Cap1.92
Enterprise Value/Revenue13.64
Enterprise Value/Gross Profit-212.05
Enterprise Value/Ebitda-1.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Unique PlatformThe company's unique platform for microbiome therapy development provides a competitive advantage, potentially leading to innovative treatments and long-term growth opportunities.
Partnerships And CollaborationsStrategic partnerships and collaborations provide Finch Therapeutics with diverse revenue streams and access to additional resources, enhancing its ability to innovate and expand its market presence.
Improved Stockholder EquityThe improvement in stockholder equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future growth.
Bears Say
Persistent LossesOngoing financial losses and high leverage pose significant risks to Finch Therapeutics' sustainability, potentially limiting its ability to invest in growth and innovation.
Negative Cash FlowsNegative cash flows highlight inefficiencies in operations and raise concerns about the company's ability to sustain its activities without external financing.
Declining RevenuesDeclining revenues reflect challenges in market demand or competitive positioning, which could hinder Finch Therapeutics' ability to achieve profitability and long-term growth.
Finch Therapeutics Group News
FNCH FAQ
What was Finch Therapeutics Group’s price range in the past 12 months?
Finch Therapeutics Group lowest stock price was $11.50 and its highest was $16.10 in the past 12 months.
What is Finch Therapeutics Group’s market cap?
Finch Therapeutics Group’s market cap is $20.19M.
When is Finch Therapeutics Group’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Finch Therapeutics Group’s earnings last quarter?
Currently, no data Available
Is Finch Therapeutics Group overvalued?
According to Wall Street analysts Finch Therapeutics Group’s price is currently Overvalued.
Does Finch Therapeutics Group pay dividends?
Finch Therapeutics Group does not currently pay dividends.
What is Finch Therapeutics Group’s EPS estimate?
Finch Therapeutics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Finch Therapeutics Group have?
Finch Therapeutics Group has 1,605,763 shares outstanding.
What happened to Finch Therapeutics Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Finch Therapeutics Group?
Currently, no hedge funds are holding shares in FNCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
0.47% Mutual Funds
1.32% Other Institutional Investors
98.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---